Wikipedia
Neuvenge
Neuvenge, Lapuleucel-T (APC 8024), is a therapeutic cancer vaccine (TCV) in development ( clinical trial) by Dendreon (DNDN). It uses the " immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge. It was first tested on breast cancer patients with tumors expressing HER2/neu, and is now scheduled to be tested on bladder cancer patients.